Thursday, September 13, 2018 4:43:34 PM
A couple of new assets will be moved into the pipeline over the next few months from the lab. OXB will talk about those soon. These match the direction of existing clients. Maybe brain (axovant) liver ( Sanofi ) etc. ?
Revenue potential looks fab. Substantial growth.
Hope to be a part of Novartis` drug progression beyond the 2nd CAR T.
Pipeline has never looked healthier in term of feasibility studies for new customers.
Enormous growth opportunities.
Mentioned process C
3 clean rooms working flat out. Bullish about 2nd half revenue.
TRiP improves by x 10 so looking at out-licensing deal of up front and royalty. Does lenti and AAV. Good IP too.
Working on an awful lot of feasibility so expect further deals over next 12 months.
Manufacturing process is difficult so a real barrier to entry for others.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM